Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, open-label safety study of MYALEPT in patients with generalized lipodystrophy

Trial Profile

A single-arm, open-label safety study of MYALEPT in patients with generalized lipodystrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Metreleptin (Primary)
  • Indications Lipodystrophy
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 07 Aug 2018 New trial record
    • 31 Jul 2018 The EC has granted marketing authorization for MYALEPTA, as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients with confirmed congenital generalized LD or acquired generalized LD in adults and children 2 years of age and above; or with confirmed familial partial LD or acquired partial LD, in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top